Pharmaceutical

Europe’s TCR immunotherapy licensing deals surge 123% above US in 2024

TCR immunotherapy is emerging as a promising, targeted approach for treating solid tumours and other indications.

Nov 23, 2024 - 06:00
Europe’s TCR immunotherapy licensing deals surge 123% above US in 2024
TCR immunotherapy is emerging as a promising, targeted approach for treating solid tumours and other indications.
Read the original article

Tags:

Previous Article

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

Next Article

Enveda raises $130m to advance AI-driven plant based drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

China’s NMPA approves Antengene’s XPOVIO for DLBCL

China’s NMPA approves Antengene’s XPOVIO for DLBCL

Jul 10, 2024

Anavex Life Sciences receives US patent for ANAVEX 2-73 (blarcamesine)

Anavex Life Sciences receives US patent for ANAVEX 2-73...

Jun 3, 2023

Opinion: Congress must reauthorize the National Advisory Committee for Seniors and Disasters

Opinion: Congress must reauthorize the National Advisor...

Nov 13, 2023